Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

GENOTOX LABORATORIES LTD

NPI: 1215272406 · AUSTIN, TX 78744 · Clinical Medical Laboratory · NPI assigned 11/29/2012

$28.96M
Total Medicaid Paid
1,367,085
Total Claims
701,593
Beneficiaries
63
Codes Billed
2018-01
First Month
2024-03
Last Month

Provider Details

Authorized OfficialMCCARTY, MATTHEW (CEO)
NPI Enumeration Date11/29/2012

Related Entities

Other providers sharing the same authorized official: MCCARTY, MATTHEW

ProviderCityStateTotal Paid
MATTHEW S MCCARTY MD INC SUSANVILLE CA $571.04

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 171,005 $2.96M
2019 355,051 $6.12M
2020 347,931 $5.65M
2021 292,471 $5.64M
2022 103,762 $4.43M
2023 90,410 $3.82M
2024 6,455 $353K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 157,391 88,049 $8.78M
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 81,603 43,912 $3.51M
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 69,466 48,312 $2.79M
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 138,281 83,795 $1.73M
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 58,620 33,379 $1.47M
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r 12,311 10,186 $706K
80361 32,108 14,996 $380K
80348 31,634 14,925 $378K
80373 31,510 14,838 $378K
80353 31,312 14,712 $378K
80365 31,522 14,849 $378K
80358 31,501 14,855 $378K
80354 32,120 14,988 $378K
80360 31,044 14,525 $377K
80359 30,679 14,362 $376K
80356 30,877 14,460 $375K
80375 30,095 13,864 $373K
80321 29,373 13,303 $371K
80367 27,999 12,766 $364K
80345 28,425 12,497 $363K
80372 29,761 13,837 $362K
80371 25,724 10,590 $361K
80355 30,379 14,087 $361K
80364 28,213 12,416 $359K
80368 29,159 13,121 $352K
80366 27,917 12,557 $347K
80357 26,373 11,403 $347K
80369 27,042 11,625 $329K
80325 25,216 11,508 $324K
80350 25,021 9,896 $309K
80337 19,636 7,283 $283K
80332 20,639 8,623 $258K
80346 14,492 7,707 $140K
80323 9,765 7,360 $115K
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 5,960 4,951 $82K
81226 1,648 1,408 $45K
81479 Unlisted molecular pathology procedure 10,148 1,070 $35K
80338 2,208 733 $31K
81241 1,602 1,366 $29K
81225 1,645 1,406 $29K
80339 2,582 1,001 $28K
81240 1,602 1,366 $24K
80330 1,355 1,119 $21K
80370 1,974 809 $21K
81401 1,652 1,340 $21K
80363 12,177 5,430 $17K
81227 1,624 1,387 $17K
81328 1,352 1,183 $15K
80362 13,746 6,126 $14K
80333 766 664 $12K
81355 1,604 1,370 $9K
80324 10,696 4,859 $8K
81291 1,612 1,375 $6K
82542 104 40 $5K
80347 283 266 $4K
80331 194 178 $3K
80351 199 183 $3K
81025 1,432 1,130 $3K
80299 173 87 $3K
81400 261 196 $755.93
80329 677 601 $529.84
80335 550 317 $461.57
80336 51 46 $451.39